BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information Letter on SGLT2 inhibitors: Updated information on the risk of diabetic ketoacidosis

Active substance: canagliflozin, dapagliflozin, empagliflozin

After completion of the European safety review by the CHMP, the pharmaceutical entrepreneurs concerned are circulating information on the recommendation to minimise the risk of diabetic ketoacidosis.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 192KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK